.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,367,102

« Back to Dashboard

Claims for Patent: 8,367,102

Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
Inventor(s): Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Phillippe (Uccle, BE)
Assignee: Galephar Pharmaceutical Research, Inc. (Juncos, PR)
Application Number:11/892,363
Patent Claims: 1. A method of treating a skin disorder, which comprises a step of orally administering to a mammal having the skin disorder, an oral pharmaceutical composition of isotretinoin, which comprises a semi-solid preparation containing at least two lipidic excipients, at least one of them being hydrophilic having a Hydrophobic Lipidic Balance (HLB) value equal to or greater than 10, the other being an oily vehicle, whereby the at least one hydrophilic lipidic excipient(s) with a HLB value of at least 10 is selected from the group consisting of glycerol macrogolglycerides; the composition being administered in an amount effective to treat the skin disorder, and wherein the skin disorder is selected from the group consisting of acne, hypertrophic lupus erythematosus, basal cell carcinoma and squamous cell carcinoma.

2. The method of claim 1, wherein at least one hydrophilic lipidic excipient of the composition has an HLB value of at least 12.

3. The method of claim 2, wherein at least one hydrophilic lipidic excipient of the composition has an HLB value of at least 13.

4. The method of claim 1, wherein the composition comprises a semi-solid preparation in which the isotretinoin is partially in suspension and/or partially in solution.

5. The method of claim 4, wherein the oily vehicle of the composition is selected from the group consisting of glycerol macrogolglycerides.

6. The method of claim 4, wherein the oily vehicle of the composition is selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, amphiphilic oil, glycerol oleate, and mixtures thereof.

7. The method of claim 4, wherein the composition comprises from 5 to 70% by weight of the oily vehicle selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, amphiphilic oil, glycerol oleate, and mixtures thereof.

8. The method of claim 4, wherein the composition contains at least one surfactant.

9. The method of claim 4, wherein the composition comprises at least one surfactant selected from the group consisting of sorbitan fatty acid esters, polysorbate compounds, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulfate, compounds of lecithin, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, polyethylene glycol, and mixtures thereof.

10. The method of claim 4, wherein the composition further comprises from 1 to 10% by weight of at least one additional surfactant.

11. The method of claim 1, wherein the composition further comprises at least one disintegrant.

12. The method of claim 11, wherein the at least one disintegrant is selected from the group consisting of povidone, crossprovidone, sodium croscaramellose, and mixtures thereof.

13. The method of claim 1, wherein the composition is a semi-solid suspension.

14. The method of claim 13, wherein the semi-solid composition is contained in a pharmaceutically-acceptable capsule.

15. The method of claim 14, in which the capsule is selected from the group consisting of hard gelatin capsules, soft gelatin capsules, hypromellose capsules, and starch capsules.

16. The method of claim 1, wherein the mammal treated is a human.

17. The method of claim 1, wherein the skin disorder is acne.

18. The method of claim 1, wherein the skin disorder is hypertrophic lupus erythematosus.

19. The method of claim 1, wherein the skin disorder is basal cell carcinoma.

20. The method of claim 1, wherein the skin disorder is squamous cell carcinoma.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc